medigraphic.com
ISSN 0185-3325 (Print)
Órgano Oficial del Instituto Nacional de Psiquiatría Ramón de la Fuente Muńiz

2017, Number 3

<< Back Next >>

Salud Mental 2017; 40 (3)

Therapeutic properties of cannabinoid drugs and marijuana in several disorders: A narrative review

Nanni ARI, del Campo SRM, Villamil SV

Language: English
References: 60
Page: 111-118
PDF size: 357.42 Kb.


ABSTRACT

Background. Anti-inflammatory, analgesic, anticonvulsant, and other effects have been attributed to cannabis, and so it has been widely used to treat several diseases. Objective. To assess the use and therapeutic effects of cannabinoid drugs and the cannabis plant in several diseases. Method. We carried out a narrative review of the literature that has reported the use of the cannabis plant (marijuana) and cannabinoid drugs (nabilone, cannabinol and dronabinol, among others). We conducted a search in Medline, Cochrane, SciELO and other web sites. Clinical, controlled, double-blind and randomized studies were included. The route of administration and the cannabinoid drugs used were assessed too. Results. Thirty-four studies were included. Nabilone was the cannabinoid drug more commonly used (12 studies), followed by delta-9-tetrahydrocannabinol (THC) (11 studies). It was also found that the marijuana plant and cannabinoid drugs were used to treat many symptoms or diseases. Two studies were reported for Gilles de la Tourette’s syndrome. Discussion and conclusion. Many scientific studies on the marijuana plant and cannabinoid drugs conclude that these are not as effective as conventional medications and thus their benefits should be taken with caution.


REFERENCES

  1. Abrams, D. I., Hilton, J. F., Leiser, R. J., Shade, S. B., Elbeik, T. A., Aweeka, F. T., ... & Deeks, S. G. (2003). Short-Term Effects of Cannabinoids in Patients with HIV-1 Infection. A Randomized, Placebo-Controlled Clinical Trial. Annals of Internal Medicine, 139(4), 258-266.

  2. Barceloux, D. G. (2012). Medical toxicology of drug abuse: synthesized chemicals and psychoactive plants. New Jersey: John Wiley & Sons.

  3. Bestard, J. A., & Toth, C. C. (2011). An Open‐Label Comparison of Nabilone and Gabapentin as Adjuvant Therapy or Monotherapy in the Management of Neuropathic Pain in Patients with Peripheral Neuropathy. Pain Practice, 11(4), 353-368.

  4. Bihl, F., Germain, C., Luci, C., & Braud, V. M. (2011). Mechanisms of NK cell activation: CD4+ T cells enter the scene. Cellular and Molecular Life Sciences, 68(21), 3457.

  5. del Bosque, J., Fernández, C., Huesca, R. S., Díaz, D. B., López, A. D. G., Mairena, A. F., & Alvarado, R. N. (2013). The Problem of Cannabis Use: the Role of the Ministry of Health. Salud Mental, 36(2), 133-142.

  6. Brady, C. M., DasGupta, R., Dalton, C., Wiseman, O. J., Berkley, K. J., & Fowler, C. J. (2004). An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis. Multiple Sclerosis, 10(4), 425-433.

  7. Carroll, C. B., Bain, P. G., Teare, L., Liu, X., Joint, C., Wroath, C., ... & Zajicek, J. P. (2004). Cannabis for dyskinesia in Parkinson disease. A randomized double- blind crossover study. Neurology, 63(7), 1245-1250.

  8. Comisión Nacional contra las Adicciones (CONADIC). (2014). El uso médico del cannabis żtiene sustento científico?. Retrieved from http://www.conadic.salud. gob.mx/publicaciones/2015/uso_medico_cannabis.pdf

  9. Crawford, S. M., & Buckman, R. (1986). Nabilone and metoclopramide in the treatment of nausea and vomiting due to cisplatinum: a double blind study. Medical oncology and tumor pharmacotherapy, 3(1), 39-42.

  10. Crippa, J. A. S., Derenusson, G. N., Ferrari, T. B., Wichert-Ana, L., Duran, F. L., Martin-Santos, R., & Filho, A. S. (2011). Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. Journal of Psychopharmacology, 25(1), 121-130.

  11. Cunningham, D., Bradley, C. J., Forrest, G. J., Hutcheon, A. W., Adams, L., Sneddon, M., & Kaye, S. B. (1988). A randomized trial of oral nabilone and prochlorperazine compared to intravenous metoclopramide and dexamethasone in the treatment of nausea and vomiting induced by chemotherapy regimens containing cisplatin or cisplatin analogues. European Journal of Cancer and Clinical Oncology, 24(4), 685-689.

  12. Devinsky, O., Marsh, E., Friedman, D., Thiele, E., Laux, L., Sullivan, J., & Wong, M. (2016). Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. The Lancet Neurology, 15(3), 270-278.

  13. Esfandyari, T., Camilleri, M., Busciglio, I., Burton, D., Baxter, K., & Zinsmeister, A. R. (2007). Effects of a cannabinoid receptor agonist on colonic motor and sensory functions in humans: a randomized, placebo-controlled study. American Journal of Physiology-Gastrointestinal and Liver Physiology, 293(1), G137-G145.

  14. Fernández-Ruiz, J., Berrendero, F., Hernández, M. L., & Ramos, J. A. (2000). The endogenous cannabinoid system and brain development. Trends in neurosciences, 23(1), 14-20.

  15. di Forti, M., Marconi, A., Carra, E., Fraietta, S., Trotta, A., Bonomo, M., & Stilo, S. A. (2015). Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study. The Lancet Psychiatry, 2(3), 233-238. doi: 10.1016/S2215-0366(14)00117-5

  16. Frank, B., Serpell, M. G., Hughes, J., Matthews, J. N. S., & Kapur, D. (2008). Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study. BMJ, 336(7637), 199-201.

  17. Freeman, R. M., Adekanmi, O., Waterfield, M. R., Waterfield, A. E., Wright, D., & Zajicek, J. (2006). The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMSLUTS). International Urogynecology Journal, 17(6), 636-641.

  18. Frytak, S., Moertel, C. G., O’fallon, J. R., Rubin, J., Creagan, E. T., O’connell, M. J., & Schwartau, N. W. (1979). Delta-9-Tetrahydrocannabinol as an Antiemetic for Patients Receiving Cancer Chemotherapy. A Comparison with Prochlorperazine and a Placebo. Annals of Internal Medicine, 91(6), 825-830.

  19. George, M., Pejovic, M. H., Thuaire, M., Kramar, A., & Wolff, J. P. (1982). Randomized comparative trial of a new anti-emetic: nabilone, in cancer patients treated with cisplatin. Biomedicine & Pharmacotherapy, 37(1), 24-27.

  20. Hermanson, D. J., & Marnett, L. J. (2011). Cannabinoids, endocannabinoids, and cancer. Cancer Metastasis Review, 30(3-4), 599-612. doi:10.1007/s10555-011-9318-8.

  21. Hohmann, A. G., & Suplita, R. L. (2006). Endocannabinoid mechanisms of pain modulation. The AAPS Journal, 8(4), E693-E708.

  22. Horváth, B., Mukhopadhyay, P., Haskó, G., & Pacher, P. (2012). The endocannabinoid system and plant-derived cannabinoids in diabetes and diabetic complications. The American Journal of Pathology, 180(2), 432-442.

  23. Hussain, S. A., Zhou, R., Jacobson, C., Weng, J., Cheng, E., Lay, J., & Sankar, R. (2015). Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: a potential role for infantile spasms and Lennox– Gastaut syndrome. Epilepsy & Behavior, 47, 138-141.

  24. Hutcheon, A. W., Palmer, J. B., Soukop, M., Cunningham, D., McArdle, C., Welsh, J., & Cash, H. (1983). A randomised multicentre single blind comparison of a cannabinoid anti-emetic (levonantradol) with chlorpromazine in patients receiving their first cytotoxic chemotherapy. European Journal of Cancer and Clinical Oncology, 19(8), 1087-1090.

  25. Jhaveri, M. D., Elmes, S. J. R., Richardson, D., Barrett, D. A., Kendall, D. A., Mason, R., & Chapman, V. (2008). Evidence for a novel functional role of cannabinoid CB2 receptors in the thalamus of neuropathic rats. European Journal of Neuroscience, 27(7), 1722-1730. doi:10.1111/j.1460-9568.2008.06162.x

  26. Jones, S. E., Durant, J. R., Greco, F. A., & Robertone, A. (1982). A multi-institutional Phase III study of nabilone vs. placebo in chemotherapy-induced nausea and vomiting. Cancer Treatment Reviews, 9, 45-48.

  27. Kluin-Neleman, J. C., Neleman, F. A., Meuwissen, O. J., & Maes, R. A. (1979). Delta 9-Tetrahydrocannabinol (THC) as an antiemetic in patients treated with cancer chemotherapy; a double-blind cross-over trial against placebo. Veterinary and human toxicology, 21(5), 338-340.

  28. van Laar M., Cruts G., van Ooyen-Houben M., Croes, E., van der Pol, P., Meijer, R., & Ketelaars, T. (2015). The Netherlands drug situation 2014: Report to the EMCDDA by the Reitox National Focal Point. Retrieved from: https://www. trimbos.nl/?act=winkeldl.download&prod=673

  29. Lamontagne, D., Lepicier, P., Lagneux, C., & Bouchard, J. F. (2006). The endogenous cardiac cannabinoid system: a new protective mechanism. Archives des Maladies du Coeur et des Vaisseaux, 99(3), 242-6.

  30. Leweke, F., Koethe, D., & Gerth, C. (2005). Cannabidiol as an antipsychotic: a double- blind, controlled clinical trial of cannabidiol versus amisulpiride in acute schizophrenia. In 15th annual symposium on cannabinoids. Cannabinoid Research Society, Clearwater Beach, FL.

  31. Lucraft, H. H., & Palmer, M. K. (1982). Randomised clinical trial of levonantradol and chlorpromazine in the prevention of radiotherapy-induced vomiting. Clinical Radiology, 33(6), 621-622.

  32. di Marzo, V., Piscitelli, F., & Mechoulam, R. (2011). Cannabinoids and endocannabinoids in metabolic disorders with focus on diabetes. Diabetes-Perspectives in Drug Therapy (pp. 75-104). Springer Berlin Heidelberg.

  33. Maas, A. I., Murray, G., Henney, H., Kassem, N., Legrand, V., Mangelus, M., & Knoller, N. (2006). Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo-controlled, clinical trial. The Lancet Neurology, 5(1), 38-45. doi:10.1016/S1474-4422(05)70253-2

  34. Maldonado, R., Valverde, O., & Berrendero, F. (2006). Involvement of the endocannabinoid system in drug addiction. Trends in neurosciences, 29(4), 225-232. doi:10.1016/j.tins.2006.01.008

  35. Malek, T. R. (2008). The biology of interleukin-2. Annual Review of Immunology, 26, 453-479.

  36. Maurer, M., Henn, V., Dittrich, A., & Hofmann, A. (1990). Delta-9-tetrahydrocannabinol shows antispastic and analgesic effects in a single case double-blind trial. European Archives of Psychiatry and Clinical Neuroscience, 240(1), 1-4.

  37. McAllister, S. D., Rigel T. C., Horowitz, M. P., Garcia, A., & Desprez, P. Y. (2007). Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells. Molecular Cancer Therapeutics, 6(11), 2921-2927.

  38. McKallip, R. J., Jia, W., Schlomer, J., Warren, J. W., Nagarkatti, P. S., & Nagarkatti, M. (2006). Cannabidiol-induced apoptosis in human leukemia cells: a novel role of cannabidiol in the regulation of p22phox and Nox4 expression. Molecular Pharmacology, 70(3), 897-908.

  39. Meiri, E., Jhangiani, H., Vredenburgh, J. J., Barbato, L. M., Carter, F. J., Yang, H. M., & Baranowski, V. (2007). Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. Current Medical Research and Opinion, 23(3), 533-543.

  40. Mortati, K., Dworetzky, B., & Devinsky, O. (2007). Marijuana: an effective antiepileptic treatment in partial epilepsy? A case report and review of the literature. Reviews in Neurological Diseases, 4(2), 103-106.

  41. Müller-Vahl, K. R., Schneider, U., Koblenz, A., Jöbges, M., Kolbe, H., Daldrup, T., & Emrich, H. M. (2002). Treatment of Tourette’s syndrome with Δ9-tetrahydrocannabinol (THC): a randomized crossover trial. Pharmacopsychiatry, 35(02), 57-61.

  42. Müller-Vahl, K. R., Schneider, U., Prevedel, H., Theloe, K., Kolbe, H., Daldrup, T., & Emrich, H. M. (2003). Δ9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: A 6-week randomized trial. The Journal of Clinical Psychiatry, 64(4), 459‐65.

  43. Neidhart, J. A., Gagen, M. M., Wilson, H. E., & Young, D. C. (1981). Comparative trial of the antiemetic effects of THC and haloperidol. The Journal of Clinical Pharmacology, 21(S1).

  44. Noyes, R., Brunk, S. F., Avery, D. H., & Canter, A. (1975). The analgesic properties of delta‐9‐tetrahydrocannabinol and codeine. Clinical Pharmacology & Therapeutics, 18(1), 84-89.

  45. Ostenfeld, T., Price, J., Albanese, M., Bullman, J., Guillard, F., Meyer, I., & Milleri, S. (2011). A randomized, controlled study to investigate the analgesic efficacy of single doses of the cannabinoid receptor-2 agonist GW842166, ibuprofen or placebo in patients with acute pain following third molar tooth extraction. The Clinical Journal of Pain, 27(8), 668-676.

  46. Pinsger, M., Schimetta, W., Volc, D., Hiermann, E., Riederer, F., & Pölz, W. (2006). Benefits of an add-on treatment with the synthetic cannabinomimetic nabilone on patients with chronic pain--a randomized controlled trial. Wiener Klinische Wochenschrift, 118(11-12), 327-335.

  47. Pooyania, S., Ethans, K., Szturm, T., Casey, A., & Perry, D. (2010). A randomized, double-blinded, crossover pilot study assessing the effect of nabilone on spasticity in persons with spinal cord injury. Archives of Physical Medicine and Rehabilitation, 91(5), 703-707.

  48. Potter, D. J., Clark, P., & Brown, M. B. (2008). Potency of Δ9–THC and other cannabinoids in cannabis in England in 2005: Implications for psychoactivity and pharmacology. Journal of Forensic Sciences, 53(1), 90-94.

  49. Press, C. A., Knupp, K. G., & Chapman, K. E. (2015). Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy. Epilepsy & Behavior, 45, 49-52.

  50. Priestman, S. G., Priestman, T. J., & Canney, P. A. (1987). A double-blind randomised cross-over comparison of nabilone and metoclopramide in the control of radiation- induced nausea. Clinical Radiology, 38(5), 543-544. doi:10.1016/S0009- 9260(87)80151-4

  51. Rea, K., Roche, M., & Finn, D. P. (2007). Supraspinal modulation of pain by cannabinoids: the role of GABA and glutamate. British Journal of Pharmacology, 152(5), 633-648.

  52. Sallan, S. E., Cronin, C., Zelen, M., & Zinberg, N. E. (1980). Antiemetics in patients receiving chemotherapy for cancer: a randomized comparison of delta-9-tetrahydrocannabinol and prochlorperazine. New England Journal of Medicine, 302(3), 135-138.

  53. Sarfaraz, S., Adhami, V. M., Syed, D. N., Afaq, F., & Mukhtar, H. (2008). Cannabinoids for cancer treatment: progress and promise. Cancer Research, 68(2), 339-342.

  54. Steele, N., Gralla, R. J., Braun Jr, D. W., & Young, C. W. (1980). Double-blind comparison of the antiemetic effects of nabilone and prochlorperazine on chemotherapy- induced emesis. Cancer Treatment Reports, 64(2-3), 219-224.

  55. Strasser, F., Luftner, D., Possinger, K., Ernst, G., Ruhstaller, T., Meissner, W., & Cerny, T. (2006). Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia- cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. Journal of Clinical Oncology, 24(21), 3394-3400.

  56. Svendsen, K. B., Jensen, T. S., & Bach, F. W. (2004). Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ, 329(7460), 253.

  57. Volicer, L., Stelly, M., Morris, J., McLaughlin, J., & Volicer, B. J. (1997). Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer’s disease. International Journal of Geriatric Psychiatry, 12, 913-919.

  58. Ware, M. A., Fitzcharles, M. A., Joseph, L., & Shir, Y. (2010). The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Anesthesia & Analgesia, 110(2), 604-610.

  59. Weber, M., Goldman, B., & Truniger, S. (2010). Tetrahydrocannabinol (THC) for cramps in amyotrophic lateral sclerosis: a randomised, double-blind crossover trial. Journal of Neurology, Neurosurgery & Psychiatry, 81(10), 1135‐1140.

  60. Wissel, J., Haydn, T., Müller, J., Brenneis, C., Berger, T., Poewe, W., & Schelosky, L. D. (2006). Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain: a double‐blind placebo‐controlled crossover trial. Journal of Neurology, 253(10), 1337-1341. doi:10.1007/s00415-006- 0218-8




2020     |     www.medigraphic.com